Shakti Ramkissoon

15.8k total citations · 2 hit papers
204 papers, 6.9k citations indexed

About

Shakti Ramkissoon is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Shakti Ramkissoon has authored 204 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Cancer Research, 68 papers in Pulmonary and Respiratory Medicine and 66 papers in Oncology. Recurrent topics in Shakti Ramkissoon's work include Cancer Genomics and Diagnostics (58 papers), Glioma Diagnosis and Treatment (43 papers) and Cancer Immunotherapy and Biomarkers (26 papers). Shakti Ramkissoon is often cited by papers focused on Cancer Genomics and Diagnostics (58 papers), Glioma Diagnosis and Treatment (43 papers) and Cancer Immunotherapy and Biomarkers (26 papers). Shakti Ramkissoon collaborates with scholars based in United States, Italy and United Kingdom. Shakti Ramkissoon's co-authors include Keith L. Ligon, Pranela Rameshwar, Steven J. Greco, Jessian L. Munoz, Jeffrey S. Ross, Sarah A. Bliss, David A. Reardon, Elaine M. Sloand, Edward R. Laws and Neal S. Young and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Shakti Ramkissoon

188 papers receiving 6.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation

2012 566 citations Shakti Ramkissoon, Keith L. Ligon et al. profile →
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

2017 362 citations Timothy F. Cloughesy, Shakti Ramkissoon et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shakti Ramkissoon United States	37	2.8k	1.9k	1.8k	1.6k	941	204	6.9k
Matija Snuderl United States	40	3.2k 1.1×	2.2k 1.2×	2.6k 1.4×	2.2k 1.4×	1.4k 1.5×	188	9.2k
John Laterra United States	60	5.2k 1.9×	1.8k 1.0×	2.1k 1.1×	2.1k 1.4×	843 0.9×	214	11.3k
Elizabeth A. Maher United States	37	3.1k 1.1×	1.9k 1.0×	2.0k 1.1×	1.2k 0.8×	751 0.8×	105	6.9k
Joanna J. Phillips United States	50	3.1k 1.1×	1.8k 1.0×	3.6k 2.0×	1.2k 0.8×	978 1.0×	180	7.9k
Do‐Hyun Nam South Korea	43	3.6k 1.3×	2.2k 1.2×	2.2k 1.2×	2.4k 1.5×	803 0.9×	144	7.1k
Seok‐Gu Kang South Korea	43	1.8k 0.6×	1.1k 0.6×	2.7k 1.5×	1.1k 0.7×	817 0.9×	211	6.2k
Felix Sahm Germany	47	2.5k 0.9×	1.4k 0.8×	3.8k 2.1×	1.1k 0.7×	1.2k 1.2×	250	8.8k
Donald M. O’Rourke United States	53	3.4k 1.2×	1.8k 1.0×	3.4k 1.9×	2.0k 1.3×	927 1.0×	210	8.9k
Katrin Lamszus Germany	53	3.8k 1.4×	2.1k 1.2×	2.5k 1.4×	2.2k 1.4×	990 1.1×	154	7.8k
Xiaobu Ye United States	39	1.3k 0.5×	889 0.5×	2.3k 1.3×	2.6k 1.7×	1.4k 1.5×	151	6.8k

Countries citing papers authored by Shakti Ramkissoon

Since Specialization

Citations

This map shows the geographic impact of Shakti Ramkissoon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shakti Ramkissoon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shakti Ramkissoon more than expected).

Fields of papers citing papers by Shakti Ramkissoon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shakti Ramkissoon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shakti Ramkissoon. The network helps show where Shakti Ramkissoon may publish in the future.

Co-authorship network of co-authors of Shakti Ramkissoon

This figure shows the co-authorship network connecting the top 25 collaborators of Shakti Ramkissoon. A scholar is included among the top collaborators of Shakti Ramkissoon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shakti Ramkissoon. Shakti Ramkissoon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Russano, Marco, Remya George, Pedro Nunes, et al.. (2024). 1352P Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy. Annals of Oncology. 35. S854–S854. 1 indexed citations

Giannoudis, Athina, Ethan Sokol, Shakti Ramkissoon, et al.. (2023). Abstract P5-14-10: Targetable alterations and genomic signatures within breast cancer brain metastases: Data from comprehensive genomic profiling of 761 breast cancer brain metastases. Cancer Research. 83(5_Supplement). P5–14. 1 indexed citations

Nesline, Mary, Rebecca A. Previs, Grace K. Dy, et al.. (2023). PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes. Cancers. 15(19). 4789–4789. 4 indexed citations

Bratslavsky, Gennady, Hanan Goldberg, Andrea Necchi, et al.. (2022). Novel synthetic lethality drug target in urothelial bladder cancer based on MTAP genomic loss. Urologic Oncology Seminars and Original Investigations. 41(2). 109.e15–109.e22. 6 indexed citations

Blenman, Kim, Malini Harigopal, Emily Reisenbichler, et al.. (2022). PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer. Breast Cancer Research and Treatment. 196(1). 221–227. 3 indexed citations

Sharaf, Radwa, Dean C. Pavlick, Garrett M. Frampton, et al.. (2021). FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas. Neuro-Oncology Advances. 3(1). vdab017–vdab017. 4 indexed citations

Huang, Richard S.P., Brennan Decker, Karthikeyan Murugesan, et al.. (2021). Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression. Journal for ImmunoTherapy of Cancer. 9(6). e002558–e002558. 8 indexed citations

Williams, Erik A., Radwa Sharaf, Brennan Decker, et al.. (2020). CDKN2C -Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53 / RB1 –Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-Codeletion. JCO Precision Oncology. 4(4). 955–971. 10 indexed citations

Williams, Erik A., Meagan Montesion, Brian M. Alexander, et al.. (2020). CYLD mutation characterizes a subset of HPV-positive head and neck squamous cell carcinomas with distinctive genomics and frequent cylindroma-like histologic features. Modern Pathology. 34(2). 358–370. 12 indexed citations

10.

Williams, Erik A., Meagan Montesion, Radwa Sharaf, et al.. (2020). CYLD-mutant cylindroma-like basaloid carcinoma of the anus: a genetically and morphologically distinct class of HPV-related anal carcinoma. Modern Pathology. 33(12). 2614–2625. 9 indexed citations

11.

Huang, Richard S.P., Shoua Yang, Nicholas Britt, et al.. (2020). Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations. JTO Clinical and Research Reports. 2(2). 100100–100100. 11 indexed citations

12.

Renfrow, Jaclyn J., M. Soike, James L. W. West, et al.. (2020). Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor. Scientific Reports. 10(1). 15195–15195. 23 indexed citations

13.

Dunn, Ian F., Ziming Du, Mehdi Touat, et al.. (2018). Mismatch Repair Deficiency in High-Grade Meningioma: A Rare but Recurrent Event Associated With Dramatic Immune Activation and Clinical Response to PD-1 Blockade. JCO Precision Oncology. 2018(2). 1–12. 51 indexed citations

14.

Alharbi, Musa, Rasha Aljelaify, Lamia Alsubaie, et al.. (2018). Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency. The Oncologist. 23(12). 1401–1406. 51 indexed citations

15.

Ross, Jeffrey S., Marwan Fakih, Siraj M. Ali, et al.. (2018). Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer. 124(7). 1358–1373. 149 indexed citations

16.

Hartmaier, Ryan J., Lee A. Albacker, Juliann Chmielecki, et al.. (2017). High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis. Cancer Research. 77(9). 2464–2475. 85 indexed citations

17.

Reardon, David A., Prafulla C. Gokhale, Sarah R. Klein, et al.. (2015). Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunology Research. 4(2). 124–135. 302 indexed citations

18.

Ziskin, Jennifer, Yael Wilnai, Greg Enns, et al.. (2014). Neuropathology. Modern Pathology. 27. 433–444. 2 indexed citations

19.

Craig, Justin M., Natalie Vena, Shakti Ramkissoon, et al.. (2012). DNA Fragmentation Simulation Method (FSM) and Fragment Size Matching Improve aCGH Performance of FFPE Tissues. PLoS ONE. 7(6). e38881–e38881. 20 indexed citations

20.

Zada, Gabriel, Whitney W. Woodmansee, Shakti Ramkissoon, et al.. (2010). Atypical pituitary adenomas: incidence, clinical characteristics, and implications. Journal of neurosurgery. 114(2). 336–344. 171 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact